Clinical Research Forum - 180308

Proteolytic activity is vital to organism homeostasis. Perturbations in host protease activity can be debilitating and result in pathological conditions. Proteolytic activity is also required for pathogenesis of viral and bacterial diseases. Thus, developing protease inhibitors as therapeutic agents is an active area of investigation. Development of cell-based assays to monitor proteolytic activity permits assessment of function within the context of the cell and enables identification of activity modulators, pointing to compounds that may serve as potential pharmaceutical agents.

From the past, pharmaceutical companies have been an example of integration from Drug Discovery through Sales, regardless of size or capabilities, affording the complete chain value of its products. Everything it needed to survive it carried out for itself. The continuous pressure to increase pharmaceutical productivity and competitive advantages, is transforming the business structure with external connections of added value. Therefore a net of operational, technical and administrative external stakeholders appears as a complex influence along the long path

How can projects be guided with success to the same objective according to these different supporting structures? Pharma management models can adopt multiple solutions depending on company size, business strategies and affordable goals according to the scope of the project and portfolio, with common tools to be used, but different dimensions in its application.

Biography

Dr. Julia Coppola holds a PhD: Biological Chemistry, University of Michigan  and an MBA: Isenberg School of Business, University of Massachusetts. Experience (U S Air Force Reserve 10 years, Operations 10 years)

Light refreshments and beverages will be provided.